Lincomycin Hydrochloride API Suppliers
Lincomycin hydrochloride is an antibiotic used to treat bacterial infections. Information on specific API (Active Pharmaceutical Ingredient) suppliers for lincomycin hydrochloride is not readily available in public databases. Pharmaceutical companies typically source APIs through direct relationships with manufacturers or specialized distributors.
How is Lincomycin Hydrochloride Used?
Lincomycin hydrochloride is primarily prescribed for serious infections caused by susceptible anaerobic bacteria and some Gram-positive aerobic bacteria. It is effective against organisms like Staphylococcus aureus and Streptococcus pyogenes. The drug works by inhibiting bacterial protein synthesis [1]. It is administered orally or intravenously [1].
What Infections Does Lincomycin Treat?
This antibiotic is used for various infections, including bone and joint infections, respiratory tract infections, and skin and soft tissue infections [1]. It is particularly useful when other antibiotics are not suitable [1].
What Are the Side Effects of Lincomycin Hydrochloride?
Common side effects of lincomycin hydrochloride can include gastrointestinal issues such as diarrhea, nausea, and abdominal pain [1]. More serious, though less common, side effects can include Clostridioides difficile-associated diarrhea, which can range from mild to life-threatening [1]. Allergic reactions are also possible [1].
When Did Lincomycin Hydrochloride First Become Available?
Lincomycin was developed in the 1960s and approved for medical use in the United States in 1970 [2].
What is the Difference Between Lincomycin and Clindamycin?
Clindamycin is a semi-synthetic derivative of lincomycin. It offers broader spectrum activity against anaerobic bacteria and generally has better absorption and efficacy than lincomycin [3]. Due to its improved properties, clindamycin has largely replaced lincomycin in many clinical applications [3].
Are There Any Patent Expirations for Lincomycin Hydrochloride?
As lincomycin hydrochloride is a well-established drug first approved in 1970, its original composition of matter patents have long expired. The development of generic versions of lincomycin hydrochloride is generally not limited by active patents on the molecule itself. Information on any potential patents related to specific manufacturing processes or formulations would require specialized patent searches.
Sources:
1. National Institute of Diabetes and Digestive and Kidney Diseases
2. Wikipedia - Lincomycin
3. PubMed Central - Clindamycin